New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy

Download All
Gain expert insights on how to test for new and emerging molecular targets and incorporate targeted agents into the care of your patients with lung cancer with downloadable slides and on-demand Webcasts from live meetings, biomarker summary handouts, and a decision support tool providing the latest individualized guidance on precision therapy for NSCLC.
Edward S. Kim, MD, FACP, FASCO
Program Director
Leora Horn, MD, MSc, FRCPC
Nathan Pennell, MD, PhD
Laura J. Tafe, MD

On-Demand Webcasts

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new and emerging molecular targets guiding lung cancer management, from the role of biomarkers in immunotherapy to insights on NTRK fusions, RET fusions, and MET exon 14–skipping mutations.

Edward S. Kim, MD, FACP, FASCO
Program Director
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: July 30, 2020 Expired: No longer available for credit

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert perspectives from a medical oncologist and molecular pathologist on biomarker testing and personalized therapy in lung cancer.

Nathan Pennell, MD, PhD Laura J. Tafe, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning MOC point Released: January 15, 2021 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings